Skip to main content

Table 4 Model utility parameters

From: Cost-effectiveness analysis of newborn screening by tandem mass spectrometry in Shenzhen, China: value and affordability of new screening technology

Parametera

Mean (range)

Reference

NS

0.900(0.850–0.950)

[48]

DD

0.843(0.792–0.881)

[49]

ND

0.840(0.700–0.850)

[71]

MR

0.790(0.590–0.840)

[71]

RD

0.670(0.580–0.740)

[72]

Alive

1

Research assumption

  1. aNS No Sequela, DD Development Delay, ND Neurological Damage, MR Mental Retardation, RD Renal Damage. The utility of the same sequela is assumed to be same across the IEMs